טוען...
Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment trial
INTRODUCTION: The Strategic Timing of AntiRetroviral Treatment (START) trial has recruited antiretroviral-naïve individuals with high CD4 cell counts from all world regions. We describe the distribution of cardiovascular (CVD) risk factors, overall and by geographic region, at study baseline. METHOD...
שמור ב:
הוצא לאור ב: | HIV Med |
---|---|
Main Authors: | , , , , , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
2015
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4341949/ https://ncbi.nlm.nih.gov/pubmed/25711323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hiv.12233 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|